Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121080 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers
A Phase 1 study of Healthy Volunteers, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 3
- Study locations
NCT02121080: Completed Phase 1 study of Healthy Volunteers, sponsored by Regeneron Pharmaceuticals.
NCT02121080 is a Phase 1 study of Healthy Volunteers that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 132 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02121080, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in cohorts of healthy adult volunteers.
Conditions Studied
Interventions
- DRUG placebo
- DRUG REGN2222(SAR438584)
Study Locations (3)
Florida
- - Daytona Beach
Indiana
- - Evansville
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
What the finished NCT02121080 record still lists
NCT02121080 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02121080 reports a single indexed study location in Florida, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT02121080 about?
NCT02121080 is a clinical study titled "Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers". This is a phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and immunogenicity of REGN2222 ascending in cohorts of healthy adult volunteers.
What is the current status of trial NCT02121080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2014-05. Estimated completion is 2015-02.
What conditions does trial NCT02121080 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT02121080?
The interventions under investigation include: placebo (DRUG), REGN2222(SAR438584) (DRUG).
Who is sponsoring clinical trial NCT02121080?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02121080 being conducted?
This trial has 3 study locations across Florida, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02121080's enrollment target sits among peer trials
132 65th of 283 higher than 217 of 283 other Healthy Volunteers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia